evolocumab
Amgen earns first Japanese nod for PCSK9 inhibitor
January 25, 2016Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol
The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …
NICE rejects Amgen’s Repatha in draft guidance
November 18, 2015Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol
NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.
FDA approves Amgen’s cholesterol lowering drug
August 28, 2015Medical Communications, Research and Development Amgen, FDA, Repatha, evolocumab
The FDA has endorsed Amgen’s cholesterol-lowering medication, Repatha, for the use in patients with high cholesterol. It follows Amgen’s successful …
NHS looks to ESC for next-gen heart drug data
August 28, 2015Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent
New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …
Amgen’s Repatha wins PCSK9 heart drug race
July 21, 2015Sales and Marketing Amgen, European Commission, PCKS9, Repatha, evolocumab, high cholesterol
The European Commission has signed off on Amgen’s Repatha, making it the first in a new class of cholesterol-lowering drugs …
Sanofi and Amgen cholesterol drugs shine
March 16, 2015Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent
Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …
Sanofi showcases alirocumab at AHA
November 20, 2014Sales and Marketing Amgen, PCSK9, Regeneron, Sanofi, aha, alirocumab, evolocumab
Sanofi and Regeneron released a battery of new Phase III data on their PCSK9 inhibitor alirocumab this week, reinforcing the …
Success for Amgen’s ‘bad’ cholesterol injection
March 18, 2014Research and Development, Sales and Marketing Amgen, LDL, PCSK9, evolocumab, hofh, tesla
An investigational PCSK9 Inhibitor from Amgen has reduced LDL-C (‘bad’ cholesterol) in patients suffering from a rare genetic disorder in …
